Kymera Therapeutics, Inc.
General ticker "KYMR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.9B (TTM average)
Kymera Therapeutics, Inc. follows the US Stock Market performance with the rate: 46.4%.
Estimated limits based on current volatility of 4.4%: low 72.38$, high 79.12$
Factors to consider:
- Total employees count: 188 (+0.5%) as of 2024
- Top business risk factors: Insufficient funding, Liquidity and credit risks, Operational and conduct risks, Intellectual property risks, Geopolitical risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [49.36$, 106.22$]
- 2026-12-31 to 2027-12-31 estimated range: [34.17$, 78.50$]
Financial Metrics affecting the KYMR estimates:
- Negative: with PPE of -22.4 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 90.64 > 64.29
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term KYMR quotes
Long-term KYMR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $78.59MM | $47.07MM | $39.21MM |
| Operating Expenses | $244.12MM | $308.71MM | $388.61MM |
| Operating Income | $-165.53MM | $-261.63MM | $-349.40MM |
| Non-Operating Income | $18.57MM | $37.78MM | $38.05MM |
| R&D Expense | $189.08MM | $240.25MM | $316.57MM |
| Income(Loss) | $-146.96MM | $-223.86MM | $-311.35MM |
| Net Income(Loss)* | $-146.96MM | $-223.86MM | $-311.40MM |
| Stockholders Equity | $394.97MM | $835.62MM | $1,579.66MM |
| Assets | $575.76MM | $978.03MM | $1,742.81MM |
| Operating Cash Flow | $-102.83MM | $-194.50MM | $-232.89MM |
| Capital expenditure | $34.48MM | $12.84MM | $1.45MM |
| Investing Cash Flow | $139.89MM | $-404.08MM | $-521.06MM |
| Financing Cash Flow | $4.19MM | $608.85MM | $990.71MM |
| Earnings Per Share** | $-2.52 | $-2.98 | $-3.69 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.